Information Provided By: 
Fly News Breaks for April 7, 2016
PFE, AGN
Apr 7, 2016 | 07:07 EDT
Citi analyst Liav Abraham lowered her price target for Allergan (AGN) to $285 post the break of the Pfizer (PFE) merger. The analyst remains constructive on Allergan's fundamentals, citing the company's strong branded growth profile and high quality earnings. Abraham keeps a Buy rating on the shares.
News For AGN;PFE From the Last 2 Days
PFE
Apr 22, 2024 | 08:13 EDT
Pfizer announced that the European Commission, or EC, has granted marketing authorization for Emblaveo for the treatment of adult patients with complicated intra-abdominal infections, or cIAI, hospital-acquired pneumonia, or HAP, including ventilator-associated pneumonia, or VAP, and complicated urinary tract infections, or cUTI, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
